Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association

作者：Jia Wang, Dian-Long Zhang, Yuting Zhang, Nan Wu, Hao Yu, Yu-Fu Guan, Zhimin Fan, Yinhua Liu, Feng Jin · 发表于：Translational Breast Cancer Research · 年份：2026 · DOI：10.21037/tbcr-2025-1-64 · 研究领域：Medicine

Background Long-term survival in early-stage breast cancer patients has markedly improved, making follow-up an increasingly prolonged phase of care. Accurate prognosis assessment and a scientifically grounded follow-up plan are essential for achieving effective and individualized chronic disease management. This guideline aims to standardize these practices in China. Methods The Chinese Society of Breast Surgery (CSBrS) convened a panel of experts. Clinical evidence was assessed according to a modified GRADE system. Recommendations were developed by integrating evidence quality with practical feasibility in the Chinese healthcare setting. A consensus voting committee of 33 breast surgeons graded the recommendation strength (Level A: ≥90% agreement; Level B: 80–89% agreement). Results This guideline centers on two core components: prognosis and follow-up. A comprehensive prognosis integrates four domains: patients’ general health, including age, genetic risk, reproductive history, and past medical history; tumor staging and histopathological characteristics; molecular features like subtype, Ki-67, BRCA mutations, and multigene assay results; and treatment factors, notably surgical margin status and adjuvant regimens. Follow-up recommendations visit frequency started with every 3–6 months, then 6–12 months, transitioning to annual lifelong checks, with adjustments based on risk. Evaluations should cover general examination, tumor-related examinations, special examinations, asse...